We are thrilled to announce that EXL01, our innovative adjunct to cancer immunotherapies, has been approved by the FDA as an investigational new drug (IND), paving the way for our first clinical program in the United States. This achievement is the result of our strong collaboration with City of Hope, a national cancer research and treatment organization.

After several successful regulatory approvals in Europe, this milestone marks a pivotal step forward for Exeliom. The IND trial will allow us to bring our scientific expertise and patient-centered mission across the Atlantic, expanding the reach of EXL01 and its potential benefit to cancer patients worldwide.

‍